ENPP1 Inhibitor RBS2418 clinical trials
Also written RBS2418.
How each study uses ENPP1 Inhibitor RBS2418 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ENPP1 Inhibitor RBS2418 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- RBS2418
- 3
Studies by the year they started
3 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Riboscience, LLC. (3)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test ENPP1 Inhibitor RBS2418.
- Apr 2027Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular CarcinomaPhase 2 · Riboscience, LLC.
- Apr 2027Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid TumorsPhase 1 · Riboscience, LLC.
Studies
Open first, then newest update. How each study uses ENPP1 Inhibitor RBS2418 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal CancerRecruitingPhase 2Riboscience, LLC.NCT06824064Written as RBS2418
- Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular CarcinomaRecruitingPhase 2Riboscience, LLC.NCT07175441Written as RBS2418
- Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid TumorsRecruitingPhase 1Riboscience, LLC.NCT05270213Written as RBS2418